Literature DB >> 12559967

Role of prostaglandin E produced by osteoblasts in osteolysis due to bone metastasis.

Tomoyasu Ohshiba1, Chisato Miyaura, Akira Ito.   

Abstract

Prostaglandin E2 (PGE2) is produced in bone mainly by osteoblasts and stimulates bone resorption. Osteolytic bone metastasis of cancers is accompanied by bone resorption. In this study, we examined the roles of PGE2 in osteolysis due to bone metastasis of breast cancer. Injection of human breast cancer cells, MDA-MB-231 (MDA-231), into nude mice causes severe osteolysis in the femur and tibia. The expression of cyclo-oxygenase-2 (COX-2) and the receptor activator of NF-kappaB ligand (RANKL), a key molecule in osteoclast differentiation, mRNAs was markedly elevated in bone with metastasis. When MDA-231 cells were cocultured with mouse calvaria, COX-2-induced PGE2 production and bone resorption progressed. The contact with MDA-231 cells could induce the expression of COX-2 and RANKL in osteoblasts by mechanisms involving MAP kinase and NF-kappaB. The blockage of PGE2 signal by indomethacin and EP4 antagonist abrogated the osteoclast formation induced by the breast cancer cells. Here, we show a PGE-dependent mechanism of osteolysis due to bone metastasis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12559967     DOI: 10.1016/s0006-291x(02)02937-6

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

Review 1.  Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.

Authors:  Jocelyn Reader; Dawn Holt; Amy Fulton
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

2.  Direct Melanoma Cell Contact Induces Stromal Cell Autocrine Prostaglandin E2-EP4 Receptor Signaling That Drives Tumor Growth, Angiogenesis, and Metastasis.

Authors:  Masaki Inada; Morichika Takita; Satoshi Yokoyama; Kenta Watanabe; Tsukasa Tominari; Chiho Matsumoto; Michiko Hirata; Yoshiro Maru; Takayuki Maruyama; Yukihiko Sugimoto; Shuh Narumiya; Satoshi Uematsu; Shizuo Akira; Gillian Murphy; Hideaki Nagase; Chisato Miyaura
Journal:  J Biol Chem       Date:  2015-10-16       Impact factor: 5.157

Review 3.  Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics.

Authors:  J Fang; Q Xu
Journal:  Clin Transl Oncol       Date:  2014-10-29       Impact factor: 3.405

4.  Increased COX2 expression enhances tumor-induced osteoclastic lesions in breast cancer bone metastasis.

Authors:  Zhigang Li; Christian Schem; Yihui H Shi; Daniel Medina; Ming Zhang
Journal:  Clin Exp Metastasis       Date:  2007-10-27       Impact factor: 5.150

Review 5.  Organotropism of breast cancer metastasis.

Authors:  Xin Lu; Yibin Kang
Journal:  J Mammary Gland Biol Neoplasia       Date:  2007-09       Impact factor: 2.673

6.  Enhancement of osteoclastogenic activity in osteolytic prostate cancer cells by physical contact with osteoblasts.

Authors:  A Shiirevnyamba; T Takahashi; H Shan; H Ogawa; S Yano; H Kanayama; K Izumi; H Uehara
Journal:  Br J Cancer       Date:  2011-01-04       Impact factor: 7.640

Review 7.  Breast cancer metastasis to the bone: mechanisms of bone loss.

Authors:  Yu-Chi Chen; Donna M Sosnoski; Andrea M Mastro
Journal:  Breast Cancer Res       Date:  2010-12-16       Impact factor: 6.466

8.  COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer.

Authors:  A V Timoshenko; C Chakraborty; G F Wagner; P K Lala
Journal:  Br J Cancer       Date:  2006-04-24       Impact factor: 7.640

Review 9.  The Role of Inflammation in Breast and Prostate Cancer Metastasis to Bone.

Authors:  Andy Göbel; Stefania Dell'Endice; Nikolai Jaschke; Sophie Pählig; Amna Shahid; Lorenz C Hofbauer; Tilman D Rachner
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

Review 10.  E-type prostanoid receptor 4 (EP4) in disease and therapy.

Authors:  Viktoria Konya; Gunther Marsche; Rufina Schuligoi; Akos Heinemann
Journal:  Pharmacol Ther       Date:  2013-03-21       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.